CCL2 and neoplasm: Indeed, tumor-antigen-specific Tregs were shown to mobilize from the bone marrow toward tumor-associated CCL2 and provide a dominant dampening of the effector response,73 and in our study, the CAR Tregs migrated to the site of Bw6+ islet.